A Phase 3 interventional study of Cabozantinib and Atezolizumab in Metastatic Prostate Cancer and Prostate Adenocarcinoma, sponsored by Exelixis. Active, not recruiting at 280 sites in 27 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by Exelixis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cabozantinib in Prostatic Neoplasms — 3 open to participants now, 6 under way, 2 of them phase 3. cabozantinib · Prostatic Neoplasms.
Among the 23 studies testing cabozantinib in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 3, and was the 16th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →3 of the 23 studies testing cabozantinib in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+ · Men only
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Exelixis · Sites in United States
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 4
First in 2009; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 575 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 33 across the 23 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 23 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 7 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing cabozantinib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05168618University of UtahCabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | 2026-11 |
| NCT05613894University of UtahDose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cabozantinib in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.
The primary objective of this study is to evaluate the efficacy of cabozantinib (XL184) in combination with atezolizumab versus a second NHT (abiraterone or enzalutamide) in subjects with mCRPC who have previously been treated with one, and only one, NHT (e.g. abiraterone, apalutamide, darolutamide, or enzalutamide) to treat metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic CRPC (M0 CRPC), or mCRPC, and who have measurable extrapelvic disease. The multiple primary efficacy endpoints comparing the experimental arm and control arm are Duration of Progression Free Survival (PFS) per RECIST 1.1 by Blinded Independent Radiology Committee (BIRC) and Duration of Overall Survival (OS). The secondary efficacy endpoint is Objective Response Rate (ORR) per RECIST 1.1 per BIRC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w
Drug: Cabozantinib · Drug: Atezolizumab
Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization
Drug: Abiraterone Acetate · Drug: Enzalutamide · Drug: Prednisone
Supplied as 20-mg tablets; administered orally daily at 40mg
Also known as: XL184, Cabometyx®
Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)
Also known as: Tecentriq®
Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid
Also known as: Abiraterone, Zytiga
Supplied as 40 mg capsules; administered orally daily at 160mg
Also known as: Xtandi
Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily
Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)
Duration of PFS was defined as the time from randomization to the earlier of either the date of radiographic progression (defined as progressive disease \[PD\] per RECIST 1.1) per BIRC or the date of death due to any cause. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with an absolute increase of ≥ 5 mm, unequivocal progression of non-target lesions and/or the appearance of new lesions.
Time frame: Up to a maximum of approximately 30 months (Median duration of follow-up was 14.31 months)
Duration of Overall Survival (OS)
Duration of OS was defined as the time from randomization to death due to any cause. For participants, who were not known to have died at the time of data cutoff and were permanently lost to follow-up, duration of OS was censored at the earlier of the following dates: date the participant was last known to be alive or date of full withdrawal of consent (including survival follow-up), or date of data cutoff. OS was calculated as earlier of date of death or censoring - date of randomization + 1)/30.4375
Time frame: Up to a maximum of approximately 45 months (Median duration of follow-up was 24.05 months)
| Milestone | Experimental Arm: Cabozantinib and Atezolizumab | Control Arm: Second Novel Hormonal Therapy (NHT) |
|---|---|---|
| Started | 289 | 286 |
| Received at least 1 dose of any study treatment | 284 | 284 |
| Received cabozantinib or atezolizumab | 284 | 0 |
| Received abiraterone and prednisone or enzalutamide | 1 | 283 |
| Discontinued radiographic follow-up | 267 | 265 |
| Discontinued survival follow-up | 202 | 202 |
| Completed | 22 | 20 |
| Not completed | 267 | 266 |
| Withdrew: No study treatment given | 4 | 3 |
| Withdrew: Radiographic disease progression | 132 | 158 |
| Withdrew: Adverse event | 79 | 43 |
| Withdrew: Lack of clinical benefit | 1 | 1 |
| Withdrew: Withdrawal by subject | 24 | 22 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Miscellaneous | 26 | 36 |
| Withdrew: Missing data/data not yet received | 1 | 0 |
Duration of PFS was defined as the time from randomization to the earlier of either the date of radiographic progression (defined as progressive disease \[PD\] per RECIST 1.1) per BIRC or the date of death due to any cause. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with an absolute increase of ≥ 5 mm, unequivocal progression of non-target lesions and/or the appearance of new lesions.
| months | Experimental Arm: Cabozantinib and Atezolizumab | Control Arm: Second NHT |
|---|---|---|
| Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC) | 6.34 (6.18 to 8.80) | 4.17 (3.71 to 5.65) |
Duration of OS was defined as the time from randomization to death due to any cause. For participants, who were not known to have died at the time of data cutoff and were permanently lost to follow-up, duration of OS was censored at the earlier of the following dates: date the participant was last known to be alive or date of full withdrawal of consent (including survival follow-up), or date of data cutoff. OS was calculated as earlier of date of death or censoring - date of randomization + 1)/30.4375
| months | Experimental Arm: Cabozantinib and Atezolizumab | Control Arm: Second NHT |
|---|---|---|
| Duration of Overall Survival (OS) | 14.78 (13.37 to 16.66) | 14.98 (13.01 to 18.50) |
Collected over Up to a maximum of approximately 45 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental Arm: Cabozantinib and Atezolizumab | 173/284 (60.9%) | 135/284 (47.5%) | 281/284 (98.9%) |
| Control Arm: Second NHT | 179/284 (63%) | 89/284 (31.3%) | 254/284 (89.4%) |
| Event | Experimental Arm: Cabozantinib and Atezolizumab | Control Arm: Second NHT |
|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 22/284 | 20/284 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 10/284 | 1/284 |
| Acute kidney injuryRenal and urinary disorders | 9/284 | 3/284 |
| PneumoniaInfections and infestations | 8/284 | 2/284 |
| Urinary retentionRenal and urinary disorders | 8/284 | 1/284 |
| AnaemiaBlood and lymphatic system disorders | 5/284 | 8/284 |
| Urinary tract infectionInfections and infestations | 7/284 | 4/284 |
| DiarrhoeaGastrointestinal disorders | 7/284 | 0/284 |
| General physical health deteriorationGeneral disorders | 3/284 | 6/284 |
| VomitingGastrointestinal disorders | 5/284 | 3/284 |
| Event | Experimental Arm: Cabozantinib and Atezolizumab | Control Arm: Second NHT |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 133/284 | 19/284 |
| Decreased appetiteMetabolism and nutrition disorders | 113/284 | 43/284 |
| FatigueGeneral disorders | 85/284 | 57/284 |
| NauseaGastrointestinal disorders | 80/284 | 36/284 |
| AstheniaGeneral disorders | 77/284 | 37/284 |
| AnaemiaBlood and lymphatic system disorders | 77/284 | 52/284 |
| Aspartate aminotransferase increasedInvestigations | 70/284 | 15/284 |
| Alanine aminotransferase increasedInvestigations | 69/284 | 9/284 |
| HypothyroidismEndocrine disorders | 65/284 | 4/284 |
| HypertensionVascular disorders | 60/284 | 20/284 |
Intent-to-treat (ITT) population: Included all participants who were randomized regardless of whether any study treatment or the correct study treatment was received.
| Age, Categorical(Participants) | Experimental Arm: Cabozantinib and Atezolizumab | Control Arm: Second NHT | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 54 | 67 | 121 |
| >=65 years | 235 | 219 | 454 |
| Sex: Female, Male(Participants) | Experimental Arm: Cabozantinib and Atezolizumab | Control Arm: Second NHT | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 289 | 286 | 575 |
| Ethnicity (NIH/OMB)(Participants) | Experimental Arm: Cabozantinib and Atezolizumab | Control Arm: Second NHT | Total |
|---|---|---|---|
| Hispanic or Latino | 77 | 72 | 149 |
| Not Hispanic or Latino | 196 | 196 | 392 |
| Unknown or Not Reported | 16 | 18 | 34 |
| Race/Ethnicity, Customized(Participants) | Experimental Arm: Cabozantinib and Atezolizumab | Control Arm: Second NHT | Total |
|---|---|---|---|
| American Indian/Alaska Native | 3 | 9 | 12 |
| Asian | 39 | 39 | 78 |
| Black/African American | 0 | 9 | 9 |
| Native Hawaiian/Pacific Islander | 1 | 0 | 1 |
| White | 227 | 213 | 440 |
| Multiple | 1 | 0 | 1 |
| Other | 2 | 3 | 5 |
| Not Reported | 16 | 13 | 29 |
Showing the first 100 of 280 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Apr 2024, 42 months.
Results were first posted in Dec 2025, 1 year 7 months after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 42 months is above that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cabozantinib · Atezolizumab